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The recent withdrawal of cerivastatin (Baycol® or Lipobay®)
from the world market generated substantial attention in the
lay media. According to press reports, the use of cerivastatin
was linked to rhabdomyolysis, which lead to kidney failure,
and was responsible for 31 fatalities in the United States and
a further 21 deaths worldwide. In addition, there were 385
nonfatal cases reported among the estimated 700,000 users
in the United States, most of whom required hospitalization.
In many of the fatal cases, patients had received the full dose
of cerivastatin (0.8 mg/day) or were using gemfibrozil
(Lopid®) concomitantly. This drug–drug interaction was
implicated in 12 of the 31 fatalities in the United States.
The media reports caused concern among the users of all
statins and triggered a large number of calls to treating
clinicians. The American Heart Association and the American
College of Cardiology took a stand, by issuing a statement
aimed at reassuring statin users that the five remaining
members of this drug grouping — lovastatin, pravastatin,
simvastatin, atorvastatin, and fluvastatin — are safe, that only
in extremely rare situations do they cause rhabdomyolysis,
and that the health benefits clearly outweigh any risks [1].
Simultaneously, however, the German government accused
Bayer of withholding vital information from its regulatory
agency [2]. Other regulatory agencies in the United States
and Europe, are reviewing the safety data or considering
changes to the labeling for the other five statins, and United
States law firms are putting advertisements in the press for
victims of rhabdomyolysis. At the time of withdrawal, Baycol®
had slightly less than 4% of the statin market in the United
States. The statin manufacturers are obviously concerned,
since worldwide sales in 2001 are projected to be US$16
billion.
This commentary will address the important clinical and
public health questions, raised by the withdrawal of
cerivastatin.
Should we continue to approve drugs based
on surrogate efficacy?
Cerivastatin, as well as other lipid-lowering agents, received
initial regulatory approval based on their effects on serum
lipoproteins. Following approval, the three fermentation-
derived statins — simvastatin, pravastatin, and lovastatin —
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Abstract
Cerivastatin was recently withdrawn from the market because of 52 deaths attributed to drug-related
rhabdomyolysis that lead to kidney failure. The risk was found to be higher among patients who
received the full dose (0.8 mg/day) and those who received gemfibrozil concomitantly. Rhabdo-
myolysis was 10 times more common with cerivastatin than the other five approved statins. We
address three important questions raised by this withdrawal. Should we continue to approve drugs on
surrogate efficacy? Are all statins interchangeable? Do the benefits outweigh the risks of statins? We
conclude that decisions regarding the use of drugs should be based on direct evidence from long-term
clinical outcome trials.
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have been shown to reduce the risk of mortality and/or major
coronary events [3]. However, the available documentation
for long-term efficacy and safety for the synthetic statins —
atorvastatin, fluvastatin, and cerivastatin — is weak or
nonexistent.
The fibrates were also approved based on surrogate efficacy,
primarily, an increase in high-density lipoprotein (HDL)-
cholesterol. Subsequently, gemfibrozil was shown to reduce
coronary events in the Veterans Affairs HDL-Cholesterol
Intervention Trial (VA-HIT), despite only a very small,
observed increase in HDL-cholesterol [4]. In contrast,
bezafibrate, in the Bezafibrate Infarction Prevention (BIP)
study, caused a marked increase in HDL-cholesterol but had
no effect on the risk of coronary events [5].
There are three major limitations associated with reliance on
surrogate efficacy. First, experience indicates that changes in
surrogate markers are poor predictors of clinical efficacy
[6,7]. Second, a drug may have multiple mechanisms of
action, and reliance on one action for regulatory approval
ignores the potential consequences of its other actions.
Statins are pleiotropic and have known effects on nitrate
oxide availability and vascular inflammation that could be of
clinical relevance. Additionally, the dose-responses for these
pleiotropic effects appear to differ from the dose-response
for the low-density lipoprotein (LDL)-cholesterol lowering
effect, at least in animal studies. This raises questions about
its recommended or optimal dose. If, in humans, these
pleiotropic effects do contribute to the mortality/morbidity
benefit of statins, and if their dose-responses are different,
then it follows that the optimal clinical dose cannot be
determined from the LDL-cholesterol reduction. Large, long-
term outcome trials would be required to determine
recommended dose and clinical efficacy. Third, small short-
term trials, designed to determine drug actions on
lipoproteins, provide insufficient data on drug safety.
Unfortunately, there are no surrogates for drug safety. The
practice of medicine ought to rely on direct scientific
evidence of both efficacy and safety, rather than on
extrapolations based on surrogate efficacy.
Are all statins interchangeable?
The withdrawal of cerivastatin demonstrates that all statins
are not interchangeable. Cerivastatin is at least 10 times
more likely than the other statins to cause fatal
rhabdomyolysis [8]. Statins may be similar in terms of clinical
efficacy, but the current documentation for atorvastatin and
fluvastatin is weak. However, several ongoing trials will
provide important efficacy and safety information on these
two agents.
In the marketing of atorvastatin and fluvastatin, it has been
implied that these two synthetic statins convey the same
clinical benefits as the fermentation-derived statins. This is a
violation of the Federal Food, Drug, and Cosmetic Act.
Accordingly, the United States Food and Drug Administration
(FDA) issued letters of warning to the manufacturers of these
products, regarding their false claims about existing health
benefits [9,10].
The best clinical trial documentation of long-term safety and
efficacy comes from large-scale trials of simvastatin and
pravastatin. A recent meta-analysis based on three placebo-
controlled trials with approximately 20,000 patients followed
for over 5 years did not reveal any serious or unexpected
adverse events [11]. None of the almost 10,000 patients
receiving pravastatin was diagnosed with rhabdomyolysis.
The practice of medicine ought to be based on scientific
evidence for each individual drug rather than presuming that
all drugs of a similar grouping are interchangeable.
Do the benefits outweigh the risks of statins?
This question can only be answered for the statins that have
been properly examined in large, long-term trials. Clinicians
can be certain that the known benefits clearly outweigh the
known risks for simvastatin and pravastatin. Documentation
for lovastatin is fairly convincing, but is still insufficient for
atorvastatin and fluvastatin.
We take the position that large, long-term trials are desirable
to evaluate individual drugs that are prescribed for lifelong
use. Initial approval of the first member of a novel class of
therapeutic agents that has potential important health care
benefits, may in some cases be justified on the basis of
surrogate efficacy. However, subsequent drugs with similar
mechanisms of action should not be rushed through the
approval process but receive careful consideration regarding
their net risk–benefit ratio and optimal dose, prior to
regulatory approval. The cerivastatin experience supports the
position that unexpected serious adverse events may not be
detected until a large number of patients have been exposed
for an extended period of time.
In relative terms, it appears that cerivastatin was inferior to
the other statins. In absolute terms, it is quite likely that the
clinical benefit of cerivastatin, yet unproven, could outweigh
the minimal risk of fatal rhabdomyolysis. Our assumption is
that the regulatory agencies worldwide might have left
cerivastatin on the market if it had been the only marketed
statin. In the presence of other statins, in particular,
simvastatin and pravastatin — cerivastatin was clearly inferior.
Concerns about patient safety tipped the regulatory decision
towards its withdrawal. It will be interesting to see if drug
inferiority in the future will be an important factor in the
regulatory decision-making process.
The issues raised in this commentary have implications, not
only for the drug approval process but perhaps more
importantly, for the public’s faith in prescription drugs.
Withdrawal of approved and widely used drugs such as
cerivastatin, because of serious life-threatening side effects,c
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erodes public confidence in the medical care system. A lack
of confidence may, in part, be responsible for the increasing
reliance of the general public on alternative medical
therapies. Approval of any drug for lifelong use on the basis
of just a few thousand patients is risky and may not serve the
public, as illustrated by the experience with cerivastatin and
several other recently withdrawn drugs.
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